• Explore /
  • Poster
  • / Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.

Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.

Abstract Video & Slides Poster

Authors

null

Laurie Helen Sehn

BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada

Laurie Helen Sehn , Martine Chamuleau , Georg Lenz , Michael Clausen , Corinne Haioun , Koji Izutsu , Andrew John John Davies , Jun Zhu , Toshiko Oki , Edith Szafer-Glusman , Rebekah Conlon , Hueiyu Chiou , David Ipe , Brian Elliott , Jun Wu , Gilles A. Salles

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04663347, NCT05578976

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7592)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7592

Abstract #

TPS7592

Poster Bd #

136b

Abstract Disclosures

Similar Posters

First Author: Lorenzo Falchi

First Author: Hua-Jay Jeffery Cherng

First Author: Mariano Provencio-Pulla

First Author: Bei Hu